Step-by-Step Guide to the CDSCO Clinical Trial Approval Process in India

The Central Drugs Standard Control Organization (CDSCO) is India’s national regulatory authority responsible for approving and overseeing clinical trials under the New Drugs and Clinical Trials (NDCT) Rules, 2019. Whether for new drugs, investigational products, biologics, or bioequivalence (BA/BE) studies, CDSCO approval is mandatory prior to trial initiation. This article provides a structured, step-by-step guide for obtaining clinical trial approval from CDSCO, including key documents, timelines, forms, and compliance requirements.

Legal and Regulatory Framework:

• NDCT Rules, 2019 (in force since March 19, 2019)
• Drugs and Cosmetics Act, 1940 (as applicable)
• CDSCO Guidance Documents and GSR Notifications

When is CDSCO Approval Required?

CDSCO approval is mandatory for the following clinical trial types in India:

• New Chemical Entities (NCEs)
• Investigational New Drugs (INDs)
• Biologicals including vaccines and biosimilars
• Global clinical trials (GCTs)
• BA/BE studies in healthy volunteers
• Medical devices (Class C & D)

Stakeholders Involved in Approval Process:

1. Sponsor: Indian or global company initiating the trial
2. Authorized Clinical Research Organization (CRO): Executes the trial and files submissions
3. Ethics Committee (EC): Reviews and approves the trial protocol locally
4. Principal Investigator (PI): Leads the study at trial sites
5. Drugs Controller General of India (DCGI): Grants trial approval on behalf of CDSCO

Step-by-Step CDSCO Approval Process:

1. Step 1: Pre-Submission Planning
   • Identify trial classification: new drug, global study, BA/BE, or post-marketing
   • Ensure Ethics Committee registration is valid and active
   • Finalize study protocol and Informed Consent Documents (ICDs)
2. Step 2: Online Registration on SUGAM Portal
   • Register sponsor/CRO account at SUGAM portal
   • Provide firm details, DSC (digital signature certificate), and upload registration documents
3. Step 3: Submission of Form CT-04
   • Form CT-04 is used to apply for permission to conduct a clinical trial
   • Include protocol, IB, preclinical data, manufacturing details, EC approval letters, PI credentials, etc.
   • Pay government fees through Bharatkosh portal
4. Step 4: Review and Queries by CDSCO
   • CDSCO may raise queries within 30–60 working days
   • Sponsor must respond with clarification, additional data, or revised documents
5. Step 5: Grant of Permission – Form CT-06
   • CDSCO issues approval via Form CT-06 allowing trial initiation
   • Valid for 2 years and includes conditions for reporting and conduct

Key Documents Required for Submission:

• Final Protocol and Synopsis
• Investigator’s Brochure
• Informed Consent Form (English + vernacular)
• Ethics Committee Approvals
• Drug Manufacturing License or Import License (Form CT-16)
• Preclinical toxicology and pharmacology reports
• Clinical trial insurance certificate
• Financial disclosure by investigators

Timelines for CDSCO Approval:

Post-Approval Obligations:

• Register trial on CTRI before enrollment
• Submit Serious Adverse Event (SAE) reports within 14 days
• Submit protocol amendments, deviations, and annual status reports
• Maintain trial master file (TMF) and ensure audit readiness

Common Pitfalls and How to Avoid Them:

• Incomplete Documentation: Use a compliance checklist from Pharma SOPs
• Delayed EC Approvals: Start EC submissions in parallel to SUGAM application
• Query Handling: Maintain a regulatory tracker for addressing CDSCO queries promptly

Integration with Global Clinical Development:

CDSCO approval aligns with international standards like ICH-GCP and frameworks from agencies such as the USFDA and EMA. Global studies can initiate India arms in parallel by aligning timelines, documentation, and protocol amendments across jurisdictions.

Conclusion:

Understanding the CDSCO clinical trial approval process is critical for pharmaceutical sponsors, CROs, and investigators conducting research in India. By following a structured submission approach, aligning documentation with NDCT rules, and ensuring timely responses to regulatory queries, applicants can expedite approvals and avoid trial delays. Platforms like Stability Studies help in trial readiness, regulatory planning, and documentation alignment throughout the approval journey.